02. Pre-clinical data (module 2)
This module will tackle the tumor microenvironment changes, of which little is known about the response to therapy and showing how they can advance tumor growth and metastases. When a chemotherapy drug is administered at the maximum tolerated dose, it causes an initial drop or initial shrinkage in tumor size followed by tumor cell repopulation, at the time between successive drug treatments.
The second part will show the differences in host effects after treatment of MTD vs metronomic chemotherapy.
Then focus will be given on the mechanisms of action and resistance of metronomic chemotherapy, and on the tumor as a derailed organ. Furthermore, you will be shown the effects of different dosages of chemotherapy over the tumor cells, the tumor microenvironment, and on the effects of chemotherapy on the immune cell landscape.
To conclude this module you will be presented on how pharmacometrics could be a valuable tool when setting up metronomic regimens, either as single agent or as part of combinatorial strategies, including immune checkpoint inhibitors.
- Lectures 20
- Quizzes 1
- Duration 1 hour
- Skill level All levels
- Language English
- Students 0
- Assessments Yes
LESSON 1 YUVAL SHAKED
Introduction: host response to anti-cancer therapy
LESSON 2 YUVAL SHAKED
The opposing host effects following LDM vs. MTD chemotherapy
LESSON 3 FRANCESCO BERTOLINI
Metronomic chemotherapy Mechanisms of action and resistance
LESSON 4 FRANCESCO BERTOLINI
Metronomic chemotherapy and the immune landscape
LESSON 5 JOSEPH CICCOLINI
Time for pharmacometrics support?
The quiz is mandatory only for those willing to achieve European CME credits. Please be aware that the ISMe® educational e-learning platform is in the process of being accredited by the European Accreditation Council for Continuing Medical Education (UEMS-EACCME)